Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Non-Alcoholic Steatohepatitis Treatment Market Valued at Present and by 2029?
The scale of the non-alcoholic steatohepatitis treatment market has surged rapidly in the past few years. This market is projected to expand from $2.6 billion in 2024 to $3.57 billion in 2025, indicating a compound annual growth rate (CAGR) of 37.5%. The boost in growth during the historical period can be credited to the increasing occurrence of NASH, growing recognition and diagnosis, alterations in lifestyle and the obesity crisis, clinical studies, access to healthcare infrastructure, regulatory backing and clinical trials.
The market size for treatment of non-alcoholic steatohepatitis is anticipated to witness a staggering growth in the coming years, elevating to “$13.57 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 39.6%. This expected surge during the forecast period can be connected to factors such as progress in drug formulation, heightened awareness of the disease, increased occurrence and risk factors, and a shift towards individualized healthcare. Significant trends anticipated during the forecast period encompass a patient-focused approach, technological progress, targeted treatment options, modifications in regulatory policies, and advancements in scientific research.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
#What Drivers Are Influencing Growth In The Non-Alcoholic Steatohepatitis Treatment Market?
The surge in insulin resistance cases is influencing the non-alcoholic steatohepatitis treatment market’s expansion. Insulin resistance is a condition in which muscle, fat, and liver cells don’t respond effectively to insulin, making it difficult for them to absorb glucose from the bloodstream and resulting in elevated blood sugar levels. It’s often associated with an unhealthy lifestyle, high sugar intake, and genetic factors. The number of insulin resistance cases has soared owing to the upswing in diabetes and other liver-related problems, all of which are addressed with non-alcoholic steatohepatitis treatment. For example, a report by the International Diabetes Federation, a Belgium-based global diabetes community in January 2022, noted that diabetes afflicts 537 million people aged 20-79, accounting for one in ten individuals. This number is set to rise to 643 million by 2030 and 783 million by 2045. Besides, the American Cancer Society, a US nonprofit cancer advocacy organization, projected in January 2024 that new liver cancer incidents would be around 41,630 in 2024, slightly higher than the 41,210 cases in 2023. Consequently, the rising occurrence of insulin resistance, fueled by multiple liver diseases and diabetes, will bolster the non-alcoholic steatohepatitis treatment market.
What Are The Main Segments Identified In The Non-Alcoholic Steatohepatitis Treatment Market Research?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
What Trends Are Currently Influencing Growth In The Non-Alcoholic Steatohepatitis Treatment Market?
The growth in the non-alcoholic steatohepatitis (NASH) drug advancement has emerged as a pivotal trend in the NASH treatment market. Numerous firms are directing their investments towards creating novel drugs with fewer side effects to combat liver diseases. For instance, in May 2022, Pfizer Inc., the American pharmaceutical and biotech company, received approval from the U.S. Food and Drug Administration (FDA) under fast-track designation to foster the development of two NASH drugs, ervogastat and clesacostat. The fast-track process was established to accelerate the development of Pfizer’s experimental combination therapy known as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi) for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Which Companies Play A Key Role In The Development Of The Non-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Get The Full Report Here:
What Are The Key Regional Developments Shaping The Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model